Astellas Pharma, Nippon Boehringer Ingelheim Seek Additional Approval for Micardis.Tokyo, Japan, July 5, 2006 - (JCN) - Astellas Pharma and Nippon Boehringer Ingelheim have filed a joint application for an additional indication of Micardis, an angiotensin angiotensin /an·gio·ten·sin/ (-ten´sin) a decapeptide hormone (a. I) formed from the plasma glycoprotein angiotensinogen by renin secreted by the juxtaglomerular apparatus. It is in turn hydrolyzed by a peptidase in the lungs to form an octapeptide (a. II), which is a powerful vasopressor and stimulator of aldosterone secretion by the adrenal cortex. This is in turn hydrolyzed to form a heptapeptide (a. II receptor blocker, with the Ministry of Health, Labor and Welfare. The two companies expect that Micardis will become applicable for the treatment of type 2 diabetic nephropathy analgesic nephropathy interstitial nephritis with renal papillary necrosis, seen with abuse of analgesics such as aspirin or acetaminophen. diabetic nephropathy the nephropathy seen in later stages of diabetes mellitus, with first hyperfiltration, renal hypertrophy, microalbuminuria, and hypertension, and later proteinuria and end-stage renal disease. . For this application, they have submitted clinical data from INNOVATION, a large-scale clinical study conducted in Japan from January 2003 to November 2006. Micardis, which is manufactured by Nippon Boehringer Ingelheim and sold by Astellas Pharma in Japan, is currently indicated for the treatment of hypertension. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion